Sygnature Discovery

NOVEMBER 29, 2023

The QN-302 Phase 1 clinical trial is a multi-site, open-label, dose-escalation and dose expansion, safety, pharmacodynamic and pharmacokinetic study of intravenous QN-302 in patients with advanced or metastatic solid tumors. A total of up to 36 patients will be enrolled in the dose escalation (Phase 1a) portion of the study.

Clinical Trials 52

Clinical Trials Treatment Trials Small Molecule 52

Sygnature Discovery

NOVEMBER 29, 2023

The QN-302 Phase 1 clinical trial is a multi-site, open-label, dose-escalation and dose expansion, safety, pharmacodynamic and pharmacokinetic study of intravenous QN-302 in patients with advanced or metastatic solid tumors. A total of up to 36 patients will be enrolled in the dose escalation (Phase 1a) portion of the study.

Clinical Trials 40

Clinical Trials Treatment Trials Small Molecule 40

Practical Cheminformatics

JANUARY 8, 2024

To address this challenge, they developed a new metric, Delta Score, which uses a panel of unrelated proteins to correct docking scores and identify “selective” molecules. A 2004 paper by Vigers and Rizzi proposed a similar strategy for docking studies. It should be noted that this isn’t a new idea. What’s old is new again.

Drugs 141

Drugs Small Molecule Bioinformatics Packaging 141